Skip to main content
Clinical Trials/NCT05024188
NCT05024188
Unknown
Not Applicable

Assessing the Potential Role of the Gut Microbiome in Modulating Physical Abilities in Humans

Assaf Harofeh MC0 sites50 target enrollmentJanuary 20, 2022

Overview

Phase
Not Applicable
Intervention
Antibiotics
Conditions
Physical Abilities
Sponsor
Assaf Harofeh MC
Enrollment
50
Primary Endpoint
Microbiome Profiling
Last Updated
4 years ago

Overview

Brief Summary

The intestinal microbiome is a microbial system that is influenced by host genetics and environmental exposures such as nutrition, stress and medications. There is a growing body of evidence indicating the significant contribution of the gut microbiome to host health and disease. Furthermore, it has been shown that exercise may modify the microbiome composition. However, important mechanistic questions related to the possible associations between exercise and the human gut microbiome remain unanswered.

In this study, the investigators are using advanced state-of-the-art measurements of physical activity level and related metabolic parameters whether there is a connection between the microbiome and physical abilities in healthy participants and whether antibiotics consumption can influence host physical abilities and glycemic responses through changes induced in microbiome composition and function.

Detailed Description

During all days of the study, participants will be connected to a continuous glucose monitor (CGM). In the second segment of the study, participants will be randomized into two groups: antibiotics or placebo, which will be consumed for 7 days. The third segment of the trial, participants will undergo an FMT/placebo administration for three consecutive days according to their randomization: participants who received antibiotics will receive FMT and participants who received placebo pills will receive placebo capsules in this segment as well. During the study, participants will collect stool and buccal samples which will be used for microbiota profiling. Furthermore, participants will undergo physical abilities test, anthropometric measurements, medical history questioners, blood and urine samples and Dual X-ray absorptiometry (DXA) test.

Registry
clinicaltrials.gov
Start Date
January 20, 2022
End Date
January 20, 2023
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Assaf Harofeh MC
Responsible Party
Sponsor Investigator
Principal Investigator

Assaf Harofeh MC

Principal Investigator

Assaf-Harofeh Medical Center

Eligibility Criteria

Inclusion Criteria

  • Age - 20-35
  • Are used to exercise in aerobic sports (running, swimming, Zumba, ball games, functional training, surfing, tennis, wrestling ext.).
  • Exercise at least twice a week, for a minimum duration of the last 6 months.

Exclusion Criteria

  • Consumption of antibiotics (PO) or probiotics 3 months prior to the first day of the experiment.
  • Diagnosis of type 1 or type 2 diabetes.
  • Pregnancy, fertility treatments, breastfeeding women six months prior to enrollment and during the study.
  • Chronic disease (e.g. AIDS, Cushing syndrome, CKD, acromegaly, hyperthyroidism etc.)
  • Cancer and recent anticancer treatment
  • Psychiatric disorders
  • Coagulation disorders
  • Gastrointestinal disorders
  • Bariatric surgery
  • Alcohol or substance abuse

Arms & Interventions

Antibiotics + FMT

7 days of antibiotics- Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day. After antibiotics administration, participants will receive 10 aFMT capsules for three consecutive days (a total of 30 capsules).

Intervention: Antibiotics

Antibiotics + FMT

7 days of antibiotics- Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day. After antibiotics administration, participants will receive 10 aFMT capsules for three consecutive days (a total of 30 capsules).

Intervention: Fecal Microbiota Transplantation

Placebo

7 days of cellules pills. After cellules pills administration, participants will receive 10 agarose capsules for three consecutive days (a total of 30 capsules).

Intervention: Cellules Pills

Placebo

7 days of cellules pills. After cellules pills administration, participants will receive 10 agarose capsules for three consecutive days (a total of 30 capsules).

Intervention: Agarose Capsules

Outcomes

Primary Outcomes

Microbiome Profiling

Time Frame: 2 years

Collection of stool and buccal samples samples for microbiome composition analysis with16s rRNA sequencing.

Body Mass Index (BMI)

Time Frame: 2 years

The BMI is defined as the body mass divided by the square of the body height, and is expressed in units of kg/m\^2

Body Circumferences

Time Frame: 2 years

waist, hips, and limbs (cm).

Secondary Outcomes

  • Glycemic Responses(2 years)
  • Bone Mineral Density (BMD)(2 years)

Similar Trials